MARLBOROUGH, Massachusetts,
Nov. 6, 2018 /PRNewswire/ -- On
November 15, 2018 Immunovia will
sponsor a unique educational symposium for primary care clinicians
in honor of World Pancreatic Cancer Day. The program will highlight
the important role that primary care clinicians can play in
detecting pancreatic adenocarcinoma early in patients. This World
Pancreatic Cancer Day, Fenway Park will be transformed into a
football field in preparation for hosting a historic rivalry game
between Harvard University and
Yale University. In honor of this, Dr.
James Farrell, Director of the Yale
Center for Pancreatic Diseases at Yale New Haven Hospital and
Professor of Medicine at Yale School of
Medicine, and A. James Moser,
Co-Director of the Pancreas & Liver Institute at the Beth
Israel Deaconess Medical Center and Associate Professor of Surgery
at Harvard Medical School, will be the
featured presenters.
Dr. James Farrell explained why
he was excited to participate in this program: "As the Director of
Yale Center for Pancreatic Diseases, my pre-occupation in patient
care is improving outcomes for patients, through early detection
and by identifying new treatments for pancreatic cancer. If we can
find patients and diagnose them earlier, before they get these
invasive cancers, it will make a world of difference for patients.
Primary care clinicians play a vital role in that effort."
Dr. James Moser, Co-Director of
the Pancreas and Liver Institute at Beth Israel Deaconess Medical
Center, and Associate Professor of Surgery at Harvard Medical School added, "While Harvard and
Yale may be rivals on the football
field, we speak with one voice on World Pancreatic Cancer Day to
refresh awareness about this dreadful disease within the primary
care community. Primary care providers are KEY to identifying
patients while they still have early pancreatic cancer and the
chance to be cured. Their strong partnership means finding families
at increased risk and referring patients for expert treatment
before the clock runs out on a disease that is now the third
leading cause of cancer death in the USA."
Cathy Griffith, President and
Founder of the Griffith Family Foundation, is a big proponent for
educating primary care clinicians on the topic of pancreatic
cancer: "Pancreatic Cancer is considered a silent killer because it
often grows or spreads before it is detectable. Primary care
clinicians CAN change the game and Sideline Pancreatic Cancer! This
can be done in their offices by being aware of the early signs and
symptoms of pancreatic cancer which includes unexplained weight
loss, loss of appetite, back or abdominal pain, and new onset
diabetes (after the age of 50). It is events like this hosted by
Immunovia that will bring about transformational change for the
global pancreatic cancer community!"
Mats Grahn, CEO Immunovia
concluded: "Immunovia is proud to sponsor primary care education on
World Pancreatic Cancer Day, a day that is meant to increase
awareness in our community about the symptoms and risks of
pancreatic cancer, and the urgent need for earlier detection."
Agenda of the symposium and other details about the event can be
accessed on www.immunovia.com.
About Immunovia
Immunovia AB was founded in 2007 by investigators from the
Department of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases
diagnosis, prognosis and therapy monitoring.
(Source: www.immunovia.com)
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
About Pancreatic Cancer
Pancreatic Cancer is one of the most deadly and difficult to detect
cancers, as the signs and symptoms are diffuse and similar to other
diseases. There are more than 40,000 deaths and over 50,000 new
cases diagnosed each year in the U.S. alone, and the five-year
survival rate for pancreatic cancer is currently 5-8 %. It is
predicted to become the second leading cause of cancer death by
2020. The majority of patients (80%) are diagnosed with pancreatic
adenocarcinoma in late stages when surgical resection (the only
effective treatment to date) is not possible. Early detection of
pancreatic cancer is the only way to improve outcomes, which is why
educating primary care physicians on the signs, symptoms and risk
factors of pancreatic cancer is so important. Early diagnosis can
significantly improve pancreatic cancer patients' 5-year survival
rates from 5-8 % to up to 49%.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/immunovia-ab/r/immunovia-sponsors-primary-care-educational-symposium-at-fenway-park-in-honor-of-world-pancreatic-ca,c2665820
The following files are available for download:
http://mb.cision.com/Main/13121/2665820/940222.pdf
|
Immunovia PR, WPCD
Fenway
|
For more information, please contact:
Mats Grahn
Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230
Email: mats.grahn@immunovia.com